ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

0Y3M Prothena Corporation Plc

14.65
0.00 (0.00%)
24 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Prothena Corporation Plc LSE:0Y3M London Ordinary Share IE00B91XRN20 PROTHENA ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 14.65 808 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 91.37M -147.03M -2.7389 -5.62 786.44M

Prothena to Report Third Quarter 2022 Financial Results on November 3rd

27/10/2022 9:05pm

GlobeNewswire Inc.


Prothena (LSE:0Y3M)
Historical Stock Chart


From Dec 2021 to Dec 2024

Click Here for more Prothena Charts.
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2022 financial results on Thursday, November 3, 2022 after the close of the U.S. financial markets.

Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on November 3.

About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Contacts:InvestorsJennifer Zibuda, Director, Investor Relations & Communications650-837-8535, jennifer.zibuda@prothena.com

MediaMichael Bachner, Senior Director, Corporate Communications609-664-7308,michael.bachner@prothena.com

1 Year Prothena Chart

1 Year Prothena Chart

1 Month Prothena Chart

1 Month Prothena Chart